On January 25, the drug clinical trial quantity value leaderboard among GCP institutes throughout the country in 2021 was unveiled. Our hospital ranks 29^th in the overall list, 20^th among general hospitals and 1^st in the northwest region.

Drug Clinical Trial Quantity Value Leaderboard is the authoritative in the clinical trial field under the leadership of Chinese Pharmaceutical Association. With the number of trial projects in recent three years and their great value, this list reflects the contribution of GCP institutes to the research and development of new drugs, operational scale and inputs and more, but it is less associated with other ranks among hospitals. The leaderboard in 2021 is formed by collecting the volumes of drug clinical trials of each clinical trial institute over three years from 2019 to 2021, including eight objective indicators, for example, total number of drug clinical trials, number of phase II-III projects, number of international multicenter projects and number of phase I leading projects, and considering their R&D value indicators and weights. The data source from real-time data on the official website of Center for Drug Evaluation, NMPA. This ranking signifies the support and cooperation of drug clinical trial institutes to national biomedical research and development.

The drug clinical trial institute of our hospital always observes the philosophy of “project quality as the core”, and gradually expands the scale on the premise of a satisfactory project quality. Especially, since “7.22” in 2015, with great concerns and support of our hospital, the institute has followed the adjustments of supervision policies for clinical trial institutes by National Health Commission of the People's Republic of China and National Medical Products Administration, formulated and released a series of management measures by combining with the facts, and strictly complied with the implementation concepts of GCP, promoting the fine construction of drug clinical trial management system of our hospital and making great progress. In 2021, a total of 224 new clinical trial projects in 40 disciplines have been initiated throughout the hospital with an increase of 111.32% compared with the last year, and the contract funds have reached RMB 130 million, increased by 81.70% compared with the last year. Compared with the previous year, both the number of projects and research funds are doubled, hitting a new high. Of those, our hospital has worked on 19 phase I clinical trial projects, 4 leading drug clinical trial projects throughout the country, and 7 leading instrument clinical trial projects. These projects have been achieved qualitative breakthroughs.